Like Ozempic and Wegovy, tirzepatides target the glucagon-like peptide 1 (GLP-1) receptor agonists, but also target the dual glucose-dependent insulinotropic polypeptide (GIP)
1 New to GLP-1s
Among these, their influence on human mesenchymal stem cells remains underexplored, despite the critical role of mesenchymal stem cells in tissue regeneration and secretion of bioactive factors
[2][8] When vomiting is a concern: Dehydration repeated vomiting prevents adequate fluid intake, which can become medically significant Electrolyte imbalance loss of fluids and stomach acid disrupts sodium, potassium, and chloride levels Inability to take other medications vomiting can prevent absorption of other essential drugs Pancreatitis (rare) severe abdominal pain accompanied by vomiting may indicate pancreatic inflammation, a rare but serious adverse event [6][8] Bowel obstruction (rare) extremely slowed gut motility in susceptible individuals can, in rare cases, progress to obstruction [2] The Mayo Clinics tirzepatide prescribing information flags severe abdominal pain, persistent vomiting, and signs of dehydration as reasons to seek immediate medical attention
10.1056/NEJMra1510062 62 WoottenD.ChristopoulosA.Marti-SolanoM.BabuM